Our proprietary NanoPortal platform technology is designed to deliver medication steadily over extended periods of time, with the aim of guaranteeing that patients consistently receive the right dose. In addition, NanoPortal has the potential to improve tolerability by avoiding concerns typically associated with medications with fluctuating drug release profiles
Unlike other extended-release therapeutic implants, NanoPortal can also deliver large hydrophilic molecules, such as peptides and proteins, potentially enabling a broader range of therapeutic applications.
Consists entirely of medication, allowing for extended treatment durations
No Moving Parts
No pumps or electronics which can add device performance risk
Allows the device to be inserted sub-dermally (below the skin) and easily removed
Can include different concentrations of drug formulas to enable various dosing durations
Vertically Aligned Structure
Consists of long, straight, adjacently-connected nanotubes that remain firmly attached to the original titanium substrate
Robust Lengths (40+ micrometers)
Maintains structural integrity and stable molecules under a variety of physiologic conditions
Flexible Tube Amounts & Pore Sizes
Can be increased or decreased, depending on the desired delivery rate of medication
Our proprietary, NanoPortal technology allows us to custom design each implant according to the specific drug molecule, intended drug release rate, implant duration and other aspects of the target product profile.
The unique flexibility of NanoPortal allows it to accommodate a wide variety of drug molecules and potentially improve the treatment of many different diseases.
When the pore is smaller than the drug molecule, the medication can’t escape the reservoir and enter the body.
No effects or efficacy
When the pore is only slightly larger than the drug molecule, you can achieve a near constant, steady rate of medication delivery.
Long-term effectiveness and the potential for improved tolerability
When the pore is much larger than the drug molecule, the rate of delivery decreases proportionally with the remaining drug concentration.
Short-term effectiveness and the potential for tolerability challenges